OnKure Therapeutics, Inc. (NASDAQ: OKUR) is a Healthcare company (Biotechnology) with a market capitalization of $125M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), OnKure Therapeutics, Inc. had a Maz Rating of 4.68 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.21), above most of its sector; its weakest was Profitability (2.78), around the middle of its sector. The other factors: Growth 3.99 (above most of its sector); Financial Health 3.90 (above most of its sector); Valuation 3.40 (valued in line with its sector). The current rating is for members: log in to see it.
At $3.08, OnKure Therapeutics, Inc. trades at 1.1x book value, with an EV/EBITDA of 0.2. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -43.4%, return on invested capital of -41.6% and a free cash flow yield of -35.2%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 18.84. Over the past 52 weeks the share price ranged from $2.01 to $5.38, with a beta of 0.30.
OnKure Therapeutics, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.